Cargando…
47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后
BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED) was a new pathologic type and uncommon in clinics. The aim of this study is to observe the relationship between clinical pathologic characteristics, imagination, biological behavior and prognosis i...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717869/ https://www.ncbi.nlm.nih.gov/pubmed/31451141 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.08.05 |
_version_ | 1783447631844868096 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED) was a new pathologic type and uncommon in clinics. The aim of this study is to observe the relationship between clinical pathologic characteristics, imagination, biological behavior and prognosis in NSCLC-NED. METHODS: The clinical data of 47 patients with NSCLC-NED admitted from January 2009 to November 2017 in the Fifth Medical Center of General Hospital of People's Liberation Army were collected. The demographic data and imaging characteristics were summarized. Pathological features, treatment and prognosis, analysis of the correlation between different factors and prognosis. RESULTS: Of the 47 patients with NSCLC-NED, the median age was 61 years (45 years-78 years), 38 males and 9 females; 37 were poorly differentiated cancer with NED, and 10 were middle differentiated cancer with NED; 2 cases of driving gene positive (1 case of EGFR sensitive mutation, 1 case of ALK fusion), objective response rate (ORR) of first-line chemotherapy was 34.5%, and median progression-free survival (PFS) was 4 months; the median overall survival (OS) was 11 months, and only 2 cases (4.2%, 2/47) of OS were over 2 years. CONCLUSION: NSCLC-NED is different from simple NSCLC or pulmonary neuroendocrine tumors. Males, ≤70 years old, severely smoking, and patients with lower tumor differentiation often have NED, and most of them are stage Ⅳ. This type of patient-driven gene positive proportion is lower than the general adenocarcinoma population, less sensitive to chemotherapy, and the overall survival is shorter, indicating a poor prognosis. |
format | Online Article Text |
id | pubmed-6717869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-67178692019-09-02 47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) with neuroendocrine differentiation (NED) was a new pathologic type and uncommon in clinics. The aim of this study is to observe the relationship between clinical pathologic characteristics, imagination, biological behavior and prognosis in NSCLC-NED. METHODS: The clinical data of 47 patients with NSCLC-NED admitted from January 2009 to November 2017 in the Fifth Medical Center of General Hospital of People's Liberation Army were collected. The demographic data and imaging characteristics were summarized. Pathological features, treatment and prognosis, analysis of the correlation between different factors and prognosis. RESULTS: Of the 47 patients with NSCLC-NED, the median age was 61 years (45 years-78 years), 38 males and 9 females; 37 were poorly differentiated cancer with NED, and 10 were middle differentiated cancer with NED; 2 cases of driving gene positive (1 case of EGFR sensitive mutation, 1 case of ALK fusion), objective response rate (ORR) of first-line chemotherapy was 34.5%, and median progression-free survival (PFS) was 4 months; the median overall survival (OS) was 11 months, and only 2 cases (4.2%, 2/47) of OS were over 2 years. CONCLUSION: NSCLC-NED is different from simple NSCLC or pulmonary neuroendocrine tumors. Males, ≤70 years old, severely smoking, and patients with lower tumor differentiation often have NED, and most of them are stage Ⅳ. This type of patient-driven gene positive proportion is lower than the general adenocarcinoma population, less sensitive to chemotherapy, and the overall survival is shorter, indicating a poor prognosis. 中国肺癌杂志编辑部 2019-08-20 /pmc/articles/PMC6717869/ /pubmed/31451141 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.08.05 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后 |
title | 47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后 |
title_full | 47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后 |
title_fullStr | 47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后 |
title_full_unstemmed | 47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后 |
title_short | 47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后 |
title_sort | 47例非小细胞肺癌伴神经内分泌分化的临床特点、治疗及预后 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717869/ https://www.ncbi.nlm.nih.gov/pubmed/31451141 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.08.05 |
work_keys_str_mv | AT 47lìfēixiǎoxìbāofèiáibànshénjīngnèifēnmìfēnhuàdelínchuángtèdiǎnzhìliáojíyùhòu AT 47lìfēixiǎoxìbāofèiáibànshénjīngnèifēnmìfēnhuàdelínchuángtèdiǎnzhìliáojíyùhòu AT 47lìfēixiǎoxìbāofèiáibànshénjīngnèifēnmìfēnhuàdelínchuángtèdiǎnzhìliáojíyùhòu AT 47lìfēixiǎoxìbāofèiáibànshénjīngnèifēnmìfēnhuàdelínchuángtèdiǎnzhìliáojíyùhòu AT 47lìfēixiǎoxìbāofèiáibànshénjīngnèifēnmìfēnhuàdelínchuángtèdiǎnzhìliáojíyùhòu AT 47lìfēixiǎoxìbāofèiáibànshénjīngnèifēnmìfēnhuàdelínchuángtèdiǎnzhìliáojíyùhòu AT 47lìfēixiǎoxìbāofèiáibànshénjīngnèifēnmìfēnhuàdelínchuángtèdiǎnzhìliáojíyùhòu |